World Health Organization's response to the COVID-19 pandemic

AI Revolutionizes HBV Vaccine Development as Global Market Grows at a CAGR of 5.33% - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 9, 2023

The HBV vaccine stands as a crucial tool in the World Health Organization's (WHO) mission to eliminate HBV by 2030.

Key Points: 
  • The HBV vaccine stands as a crucial tool in the World Health Organization's (WHO) mission to eliminate HBV by 2030.
  • Since the approval of the first HBV vaccine in 1981, significant advancements have occurred in the development of HBV vaccines.
  • The United States leads the global market due to a high demand for the HBV vaccine, driven by ongoing HBV infection threats.
  • The integration of AI in vaccine and drug design is poised to accelerate vaccine development, enhance efficacy, and drive the HBV vaccine market's growth.

Haier's Odyssey in the Middle East and Africa: Forging a Global Brand through Localized Innovation.

Retrieved on: 
Tuesday, October 17, 2023

Recently, Ifeng.com's premiere of "Chinese Brands Enhancing Life in the Middle East and Africa through Innovation" detailed Haier's dynamic branding in these regions.

Key Points: 
  • Recently, Ifeng.com's premiere of "Chinese Brands Enhancing Life in the Middle East and Africa through Innovation" detailed Haier's dynamic branding in these regions.
  • Considering the cultural and habit differences across countries and regions, it's tough for global companies to market identical products everywhere.
  • Using a three-fold approach of localized R&D, production, and marketing, Haier has opened up more possibilities for enhancing the lives of local consumers.
  • Today, innovative technology and product solutions tailored to local needs have made their way into millions of homes across the Middle East and Africa.

Global Adult Vaccines Market Research Report 2023: Market to Surpass $25 Billion by 2027 - Long-term Forecasts to 2032 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 11, 2023

Various technologies are harnessed to develop these vaccines, encompassing live attenuated vaccines, inactivated viral or bacterial vaccines, toxoid vaccines, recombinant vaccines, and conjugate vaccines.

Key Points: 
  • Various technologies are harnessed to develop these vaccines, encompassing live attenuated vaccines, inactivated viral or bacterial vaccines, toxoid vaccines, recombinant vaccines, and conjugate vaccines.
  • The adult vaccines market research report is an invaluable resource, offering a wealth of statistics on the adult vaccines market, including global market size, regional distributions, insights into market competitors with their respective market shares, comprehensive segmentation of the adult vaccines market, prevailing market trends, and promising opportunities.
  • These alarming statistics underscore the pivotal role of adult vaccines in curbing the spread of contagious diseases and substantiate the burgeoning growth of the adult vaccines market.
  • The adult vaccines market encompasses the sales of mRNA vaccines and viral vector vaccines.

Codagenix Announces Late-Breaking Presentation of Positive Clinical Immunogenicity Data For COVID-19 Vaccine Candidate CoviLiv™ at IDWeek 2023

Retrieved on: 
Wednesday, October 11, 2023

FARMINGDALE, N.Y., Oct. 11, 2023 /PRNewswire/ -- Codagenix Inc., a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology therapeutics, today announced the late-breaking presentation of positive clinical data for its CoviLiv™ COVID-19 vaccine candidate at the upcoming IDWeek 2023 annual meeting, taking place in Boston on October 11-15, 2023.

Key Points: 
  • Data show that participants who received two doses of 5x106 PFU of CoviLiv showed robust induction of both humoral and cellular immune responses.
  • T cell reactivity was demonstrated to be specific for multiple viral antigens beyond the frequently mutating spike protein.
  • The vaccine was designed using the Codagenix platform technology that re-codes the genetic material of a virus – converting the virus from a disease-causing pathogen into a stable and safe, live-attenuated vaccine.
  • SIIPL, the world's largest vaccine manufacturer by number of doses produced and sold globally, is manufacturing the vaccine for this clinical study.

ApiJect Systems, Corp. Bolsters Global Health Team with Esteemed Anthropologist and Leading Expert on Vaccine Hesitancy, Dr. Heidi J. Larson, as Senior Advisor

Retrieved on: 
Wednesday, October 4, 2023

Dr. Larson is best known for groundbreaking research that advances the medical, scientific, social, and political understanding of vaccine hesitancy.

Key Points: 
  • Dr. Larson is best known for groundbreaking research that advances the medical, scientific, social, and political understanding of vaccine hesitancy.
  • She has engaged in effective advocacy for better health education and policies by building consensus and critical partnerships that influence health interventions and shape policies.
  • She is the Founder and Director of The Vaccine Confidence Project, which since 2010 has worked throughout the world to overcome vaccine hesitancy.
  • She has published extensively on the topic, including her book, STUCK: How Vaccine Rumors Start—and Why They Don't Go Away.

New global study discovers people in pain feel more socially excluded than ever

Retrieved on: 
Thursday, September 28, 2023

The global index has been exploring the real impact pain has on people’s lives for almost a decade.

Key Points: 
  • The global index has been exploring the real impact pain has on people’s lives for almost a decade.
  • 42% of people questioned said they regularly experience loneliness when in pain.
  • Dr Linda Papadopoulos, Psychologist and Author, commented: “Everyday pain is a health issue that can easily be dismissed or trivialised.
  • The HPI shows that we can lessen the social and emotional impact of pain by shifting perceptions and conversations around pain management.

Prefilled Syringes Market Size & Share Analysis Report 2023 - Global Growth Trends & Forecasts to 2028 Featuring Key Players - BD & Co, Terumo, Gerresheimer, SCHOTT, & West Pharmaceutical Services - ResearchAndMarkets.com

Retrieved on: 
Friday, September 22, 2023

The "Prefilled Syringes Market Size & Share Analysis - Growth Trends & Forecasts (2023-2028)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Prefilled Syringes Market Size & Share Analysis - Growth Trends & Forecasts (2023-2028)" report has been added to ResearchAndMarkets.com's offering.
  • Notable companies operating in the prefilled syringes market include Becton, Dickinson, and Company, Terumo Corporation, Gerresheimer AG, SCHOTT, West Pharmaceutical Services, Inc., and West Pharmaceutical Services, Inc., among others.
  • The global prefilled syringes market experienced a positive impact from the COVID-19 pandemic, primarily due to the potential use of prefilled syringes for COVID-19 vaccines.
  • This transition from vials to prefilled syringes was aimed at addressing the cost and complexity of vaccine administration.

Dime Celebrates Successful New York Launch, Unveils Innovative Approach to Gen Z Connections

Retrieved on: 
Wednesday, September 6, 2023

New York, New York--(Newsfile Corp. - September 6, 2023) - Dime, the pioneering Gen Z marketing platform, celebrates a successful launch in New York City, marking a significant milestone in its mission to revolutionize how companies connect to Gen Z.

Key Points: 
  • New York, New York--(Newsfile Corp. - September 6, 2023) - Dime, the pioneering Gen Z marketing platform, celebrates a successful launch in New York City, marking a significant milestone in its mission to revolutionize how companies connect to Gen Z.
  • Dime recently hosted an exclusive event at the Four Seasons Downtown Hotel in New York to announce its official launch in the city and to welcome its extensive ambassador community.
  • With a presence spanning over 35 universities in the US, UK, and Canada, Dime's grasp on this new generation is evident.
  • Dime's debut in New York facilitated the creation of new relationships and formation of distinct communities across universities and within the Gen Z market.

Samsung Biologics releases 2023 ESG Report, reaffirming its commitment to net-zero progress and corporate social responsibility

Retrieved on: 
Tuesday, July 18, 2023

INCHEON, South Korea, July 18, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940), a global contract development and manufacturing organization (CDMO), today released its 2023 Environmental, Social and Governance (ESG) Report.

Key Points: 
  • INCHEON, South Korea, July 18, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940), a global contract development and manufacturing organization (CDMO), today released its 2023 Environmental, Social and Governance (ESG) Report.
  • "Samsung Biologics is fully committed to engaging in sustainable business practices for the positive impact it has on our clients, society, and the wider community," said John Rim, President and CEO of Samsung Biologics.
  • Samsung Biologics also hosted representatives from the World Health Organization's human resource training hub to offer biologics development and manufacturing courses.
  • "Samsung Biologics is engaged in this work because we want to leave the world better than we found it," Rim added.

QIAGEN’s QuantiFERON-TB Gold Plus shows unique clinical value with CD8 technology in new meta-analysis of tuberculosis screening

Retrieved on: 
Thursday, June 15, 2023

The study highlights QIAGEN’s continued leadership in TB infection screening, centered on QuantiFERON-TB Gold Plus test, an interferon-gamma release assay (IGRA).

Key Points: 
  • The study highlights QIAGEN’s continued leadership in TB infection screening, centered on QuantiFERON-TB Gold Plus test, an interferon-gamma release assay (IGRA).
  • The meta-analysis on QuantiFERON testing was conducted by Universitas Padjadjaran, Indonesia, and published in Clinical Chemistry and Laboratory Medicine (CCLM) [1] .
  • QuantiFERON-TB Gold Plus is the world’s leading IGRA blood test, with millions of tests performed annually.
  • [1] Darmawan, Guntur et al: "Comparison of interferon-gamma production between TB1 and TB2 tubes of QuantiFERON-TB Gold Plus: a meta-analysis" Clinical Chemistry and Laboratory Medicine (CCLM), 2023. https://doi.org/10.1515/cclm-2023-0293